Analyst Ratings For NASDAQ:EBIO – Eleven Biotherapeutics (NASDAQ:EBIO)
Today, Laidlaw initiated coverage on NASDAQ:EBIO – Eleven Biotherapeutics (NASDAQ:EBIO) with a Buy with a price target of $8.00.
Some recent analyst ratings include
- 5/10/2018-Laidlaw initiated coverage with a Buy rating.
Recent Insider Trading Activity For NASDAQ:EBIO – Eleven Biotherapeutics (NASDAQ:EBIO)
NASDAQ:EBIO – Eleven Biotherapeutics (NASDAQ:EBIO) has insider ownership of 21.00% and institutional ownership of 13.99%.
- On 9/28/2016 Abbie Celniker, Director, sold 10,031 with an average share price of $3.00 per share and the total transaction amounting to $30,093.00.
- On 9/23/2016 Ventures Fund 2007 L Flagship, Major Shareholder, sold 443,422 with an average share price of $3.16 per share and the total transaction amounting to $1,401,213.52.
- On 9/21/2016 Ventures Fund Iv L.P Flagship, Major Shareholder, sold 322,723 with an average share price of $3.75 per share and the total transaction amounting to $1,210,211.25.
- On 9/20/2016 Ventures Fund Iv L.P Flagship, Major Shareholder, sold 53,917 with an average share price of $3.39 per share and the total transaction amounting to $182,778.63.
- On 9/19/2016 Ventures Fund Iv L.P Flagship, Major Shareholder, sold 9,700 with an average share price of $3.31 per share and the total transaction amounting to $32,107.00.
- On 9/15/2016 Ventures Fund 2007 L Flagship, Major Shareholder, sold 46,692 with an average share price of $4.18 per share and the total transaction amounting to $195,172.56.
- On 9/7/2016 Ventures Fund 2007 L Flagship, Major Shareholder, sold 129,497 with an average share price of $4.54 per share and the total transaction amounting to $587,916.38.
Recent Trading Activity for NASDAQ:EBIO – Eleven Biotherapeutics (NASDAQ:EBIO)
Shares of NASDAQ:EBIO – Eleven Biotherapeutics closed the previous trading session at 2.69 down -0.14 4.78% with 3.0 shares trading hands.